Psychology Patient
8.jpg

ACTIVE STUDIES

The KAPER Lab is leading two stage I clinical trials that are examining "integrative ketamine assisted psychotherapy" or "iKAP" for the treatment of major depression (study 1) and co-existing major depression and early cognitive decline (study 2). Both studies will be conducted at the integrative outpatient medical clinic, Forum Health, which is located in Orem, Utah; and led by the site principal investigator, Dr. Andrew Petersen.

 

Specifically, our team is evaluating initial feasibility and signals of improvement in outcome measures. Results will ultimately inform a future stage II feasibility randomized controlled trial. These studies are currently under review at the University of Utah Institutional Review Board. Recruitment from the Greater Salt Lake City area is anticipated to start in late July of 2021.

3.jpeg

CLINICAL STUDY (1): IRB_00141994                                                  

INTEGRATIVE KETAMINE ASSISTED PSYCHOTHERAPY (iKAP) FOR ADULTS WITH MAJOR DEPRESSIVE DISORDER

PRINCIPAL INVESTIGATOR:

CO-PRINCIPAL INVESTIGATOR:

SITE PRINCIPAL INVESTIGATOR:

Patricia Henrie-Barrus, PhD

Anya Ragnhildstveit

Andrew Petersen, DO

STUDY LOCATION:

Forum Health, Orem, UT

STUDY MANAGER:

Sarah Cunningham

FUNDING SOURCE:

Industry Sponsor

PARTICIPATING THERAPISTS:

Joshua Cooke, CMHC, Joanna Baker, CSW, and Miranda Powers, CSW 

PARTICIPATING INSTITUTIONS:

University of Utah (primary), University of Utah School of Medicine, Utah Valley University, Harvard University, Yale University School of Medicine, and Baylor College of Medicine

STUDY AIMS & OBJECTIVES:

a3_edited.png

This study aims to develop and explore the feasibility and potential of “integrative ketamine assisted psychotherapy” (iKAP): a novel interdisciplinary intervention that combines repeated sessions of low-dose ketamine with psychotherapy, mind-body skills, ambient music, and textile art for adults with major depressive disorder (MDD). We plan on following the NIH Stage Model for behavioral intervention development, beginning with a small non-randomized pilot study to explore initial feasibility and acceptability, as well as highlight improvements in depressive symptoms and relevant outcomes. This study will ultimately inform adaptations to the intervention and study procedures in preparation for a future randomized controlled trial (RCT). Twelve participants in total will be enrolled.

FEASIBILITY STUDY
SIRB MODEL
INDUSTRY FUNDED
IRB PENDING
NOT RECRUITING YET
N = 12 PARTICIPANTS
3.jpeg

CLINICAL STUDY (2): IRB_00142093

INTEGRATIVE KETAMINE ASSISTED PSYCHOTHERAPY (iKAP) FOR OLDER ADULTS WITH CO-MORBID MAJOR DEPRESSIVE DISORDER MILD COGNITIVE IMPAIRMENT

PRINCIPAL INVESTIGATOR:

CO-PRINCIPAL INVESTIGATOR:

SITE PRINCIPAL INVESTIGATOR:

Patricia Henrie-Barrus, PhD

Anya Ragnhildstveit

Andrew Petersen, DO

STUDY LOCATION:

Forum Health, Orem, UT

STUDY MANAGER:

Sarah Cunningham

FUNDING SOURCE:

Industry Sponsor

PARTICIPATING THERAPISTS:

Joshua Cooke, CMHC, Joanna Baker, CSW, and Miranda Powers, CSW 

PARTICIPATING INSTITUTIONS:

University of Utah (primary), University of Utah School of Medicine, Utah Valley University, Harvard University, Yale University School of Medicine, and Baylor College of Medicine

STUDY AIMS & OBJECTIVES:

a3_edited.png

This study aims to explore the feasibility and potential of “integrative ketamine assisted psychotherapy” (iKAP): a novel interdisciplinary intervention that combines repeated sessions of low-dose ketamine with psychotherapy, mind-body skills, ambient music, and textile art for older adults with co-existing major depressive disorder (MDD) and mild cognitive impairment (MCI). We plan on following the NIH Stage Model for behavioral intervention development, beginning with a small non-randomized pilot study to explore initial feasibility and acceptability, as well as highlight improvements in both depressive and cognitive symptoms and relevant outcomes. This study will ultimately inform adaptations to the intervention and study procedures in preparation for a future randomized controlled trial (RCT). Four participants in total will be enrolled.​

FEASIBILITY STUDY
SIRB MODEL
INDUSTRY FUNDED
IRB PENDING
NOT RECRUITING YET
N = 4 PARTICIPANTS

INTERESTED IN PARTICIPATING IN A STUDY?